Abstract
Objective: To evaluate the impact of disease duration of pharmacoresistant focal epilepsy and type of antiepileptic therapy on intraoperative infusion therapy parameters. Materials and Methods: A retrospective cohort study was conducted involving 102 patients (2019–2024) who underwent neurosurgical intervention for pharmacoresistant focal epilepsy. Patients were stratified by disease duration (≤15 years and >15 years) and therapy type (monotherapy and polytherapy). The following parameters were evaluated: infusion volume, infusion therapy composition, fluid balance, urine output, blood loss, extubation time, and length of stay in the intensive care unit. Results: Polytherapy was associated with significantly higher fluid balance and greater crystalloid volume compared to monotherapy (p<0.05). Prolonged disease course (>15 years) was accompanied by a tendency toward increased fluid balance and significantly prolonged time to extubation (p<0.05). Hemodynamic parameters remained stable across all groups. Conclusion: The type of antiepileptic therapy and disease duration are significant factors influencing infusion therapy volume. A personalized approach to infusion management in patients with pharmacoresistant epilepsy may enhance safety and improve outcomes.